[Stevens-Johnson syndrome in the literature and authors' own studies]

Area of Science:

• Dermatology
• Toxicology
• Pharmacology

Background:

• Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), also known as Lyell Syndrome, are severe, life-threatening mucocutaneous reactions often triggered by medications.
• These conditions present with widespread epidermal detachment, mucosal erosions, and potential systemic involvement, posing significant clinical challenges.
• Current treatment protocols for SJS/TEN lack standardization, with ongoing research exploring various therapeutic agents.

Observation:

• The authors report the case of a 13-year-old male admitted to a pediatric surgery department specializing in burn treatment.
• The patient presented with symptoms suggestive of Stevens-Johnson Syndrome, with clarithromycin identified as the probable causative agent.
• Clinical management included immunoglobulin therapy, cytostatics, antimicrobial and antiviral agents, alongside standard burn wound care.

Findings:

• The implemented treatment regimen, combining systemic therapies with topical wound management, yielded positive clinical outcomes for the patient.
• This case highlights the potential efficacy of a multidisciplinary approach in managing severe cutaneous adverse drug reactions.
• Despite the positive results, the treatment of SJS/TEN remains complex and resource-intensive.

Implications:

• The case underscores the need for standardized treatment guidelines for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis to improve patient outcomes.
• Further research and clinical trials are crucial to establish evidence-based therapeutic strategies for these severe drug reactions.
• Effective management requires a comprehensive approach, integrating expertise from various medical specialties and relying on current literature and clinical experience.